Comparison of cilostazol and clopidogrel after successful coronary stenting

Seung Whan Lee, Seong Wook Park, Myeong Ki Hong, Cheol Whan Lee, Young Hak Kim, Jae Hyeong Park, Su Jin Kang, Ki Hoon Han, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

Original languageEnglish
Pages (from-to)859-862
Number of pages4
JournalAmerican Journal of Cardiology
Volume95
Issue number7
DOIs
Publication statusPublished - 2005 Apr 1

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Comparison of cilostazol and clopidogrel after successful coronary stenting'. Together they form a unique fingerprint.

  • Cite this

    Lee, S. W., Park, S. W., Hong, M. K., Lee, C. W., Kim, Y. H., Park, J. H., Kang, S. J., Han, K. H., Kim, J. J., & Park, S. J. (2005). Comparison of cilostazol and clopidogrel after successful coronary stenting. American Journal of Cardiology, 95(7), 859-862. https://doi.org/10.1016/j.amjcard.2004.12.012